Skip to main content
Log in

Compensation inflation remains consistent at private life science companies

  • Careers and Recruitment
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Non-founder total target cash compensation increased 3.3% at private life science companies in 2015.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2: Screenshot of a sample CompStudy base salary histogram from a 2015 survey.
Figure 3

References

  1. Rychlik, B. Nat. Biotechnol. 33, 313–316 (2015). Medline

    Article  CAS  Google Scholar 

  2. Rychlik, B. Nat. Biotechnol. 32, 393–395 (2014). Medline

    Article  CAS  Google Scholar 

  3. Wasserman, N. The Founder's Dilemmas: Anticipating and Avoiding the Pitfalls That Can Sink a Startup (Princeton Univ. Press, 2012).

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bruce Rychlik.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rychlik, B. Compensation inflation remains consistent at private life science companies. Nat Biotechnol 34, 667–670 (2016). https://doi.org/10.1038/nbt.3604

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3604

  • Springer Nature America, Inc.

This article is cited by

Navigation